Dr. Brahmer Discusses Frontline Single-Agent Pembrolizumab in Lung Cancer

Julie R. Brahmer, MD, affiliate professor of oncology, co-director of the Higher Aerodigestive Division, Bloomberg Kimmel Institute for Most cancers Immunotherapy, Johns Hopkins Medication, discusses pembrolizumab (Keytruda) within the first-line therapy of non–small cell lung most cancers in the course of the fifth Annual Miami Lung Most cancers Convention.The primary-line therapy of non–small cell lung most cancers has modified dramatically up to now yr and a half, Brahmer says. Sufferers with excessive PD-L1 expression now have the chance to obtain pembrolizumab as a single-agent therapy.The KEYNOTE-024 examine randomized sufferers with out EGFR or ALK rearrangements to obtain pembrolizumab or customary platinum-containing chemotherapy. Primarily based on information seen over the previous yr, sufferers who obtained single-agent pembrolizumab upfront had a major enchancment in general survival and progression-free survival. Brahmer extremely recommends testing for PD-L1 standing previous to beginning remedy, and providing single-agent pembrolizumab if the affected person has excessive PD-L1 expression.


Please enter your comment!
Please enter your name here